Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Cash, cash equivalents and short term investments | 39.95%237.96M | 39.95%237.96M | 18.29%258.37M | 20.73%309.96M | 235.67%355.6M | 22.89%170.03M | 22.89%170.03M | 60.37%218.43M | 314.31%256.74M | 22.47%105.94M |
-Cash and cash equivalents | 196.71%66.66M | 196.71%66.66M | 63.62%34.55M | -65.17%35.62M | 271.12%96.49M | -51.53%22.47M | -51.53%22.47M | 12.12%21.12M | 376.79%102.27M | -56.32%26M |
-Short-term investments | 16.09%171.3M | 16.09%171.3M | 13.43%223.82M | 77.61%274.35M | 224.14%259.1M | 60.37%147.56M | 60.37%147.56M | 68.11%197.31M | 281.23%154.47M | 196.26%79.94M |
Receivables | 243.86%3.47M | 243.86%3.47M | 810.38%2.9M | 282.48%2.62M | 484.67%1.53M | 3,507.14%1.01M | 3,507.14%1.01M | 715.38%318K | 1,914.71%685K | 605.41%261K |
-Accounts receivable | 243.86%3.47M | 243.86%3.47M | 810.38%2.9M | 282.48%2.62M | 484.67%1.53M | 3,507.14%1.01M | 3,507.14%1.01M | 715.38%318K | 1,914.71%685K | 605.41%261K |
Inventory | -39.37%231K | -39.37%231K | 89.29%636K | 240.12%585K | --514K | --381K | --381K | --336K | --172K | ---- |
Other current assets | -11.66%4.53M | -11.66%4.53M | 56.28%6.71M | 25.33%7.68M | 109.35%7.01M | 106.77%5.13M | 106.77%5.13M | --4.29M | --6.12M | --3.35M |
Total current assets | 39.45%246.19M | 39.45%246.19M | 20.25%268.61M | 21.66%320.84M | 232.87%364.65M | 25.33%176.55M | 25.33%176.55M | 60.63%223.37M | 306.36%263.72M | 23.88%109.55M |
Non current assets | ||||||||||
Net PPE | -2.60%7.32M | -2.60%7.32M | -8.63%7.15M | -15.60%7.14M | -16.53%7.2M | -11.41%7.51M | -11.41%7.51M | 739.16%7.82M | 717.49%8.46M | 655.43%8.63M |
-Gross PPE | -21.97%9.4M | -21.97%9.4M | -25.43%9.11M | -29.33%8.98M | -6.60%11.88M | -3.31%12.05M | -3.31%12.05M | 99.90%12.21M | 513.57%12.7M | 108.44%12.72M |
-Accumulated depreciation | 54.03%-2.09M | 54.03%-2.09M | 55.34%-1.96M | 56.72%-1.84M | -14.31%-4.68M | -13.91%-4.54M | -13.91%-4.54M | 15.18%-4.39M | -309.66%-4.24M | 17.45%-4.1M |
Goodwill and other intangible assets | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M |
-Goodwill | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M | 0.00%44.54M |
Other non current assets | -55.56%368K | -55.56%368K | 11.44%828K | --828K | --828K | 100.97%828K | 100.97%828K | -89.60%743K | ---- | ---- |
Total non current assets | -1.24%52.23M | -1.24%52.23M | -1.11%52.52M | -0.93%52.51M | -1.12%52.57M | -1.03%52.88M | -1.03%52.88M | 0.92%53.11M | 11.76%53M | 11.36%53.17M |
Total assets | 30.07%298.42M | 30.07%298.42M | 16.15%321.12M | 17.88%373.36M | 156.41%417.22M | 18.08%229.43M | 18.08%229.43M | 44.24%276.48M | 181.97%316.72M | 19.49%162.72M |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Payables | 2.86%14.8M | 2.86%14.8M | 17.99%14.2M | 16.37%12.22M | -21.76%8.07M | 38.42%14.39M | 38.42%14.39M | 27.68%12.04M | 42.93%10.5M | 10.62%10.31M |
-accounts payable | 2.86%14.8M | 2.86%14.8M | 17.99%14.2M | 16.37%12.22M | -21.76%8.07M | 38.42%14.39M | 38.42%14.39M | 27.68%12.04M | 42.93%10.5M | 10.62%10.31M |
Current accrued expenses | 132.03%14.56M | 132.03%14.56M | 2.29%9.38M | -23.06%5.19M | 70.73%7.55M | 71.64%6.28M | 71.64%6.28M | 381.71%9.17M | 53.54%6.75M | -26.66%4.42M |
Current debt and capital lease obligation | -8.99%1.18M | -8.99%1.18M | 0.77%1.3M | 0.00%1.29M | 0.00%1.29M | 0.00%1.29M | 0.00%1.29M | -8.18%1.29M | 63.62%1.29M | 37.34%1.29M |
-Current capital lease obligation | -8.99%1.18M | -8.99%1.18M | 0.77%1.3M | 0.00%1.29M | 0.00%1.29M | 0.00%1.29M | 0.00%1.29M | -8.18%1.29M | 63.62%1.29M | 37.34%1.29M |
Current liabilities | 43.43%45.25M | 43.43%45.25M | 11.73%36.05M | 6.77%27.88M | 14.86%23.4M | 36.14%31.55M | 36.14%31.55M | 74.90%32.26M | 54.84%26.11M | 7.75%20.37M |
Non current liabilities | ||||||||||
Long term debt and capital lease obligation | 2.34%107.22M | 2.34%107.22M | -4.60%99.9M | -4.56%99.5M | 93.29%104.95M | 94.01%104.77M | 94.01%104.77M | 258.32%104.71M | 323.23%104.25M | 120.95%54.3M |
-Long term debt | 0.79%100.3M | 0.79%100.3M | 0.63%99.9M | 0.74%99.5M | 104.47%99.87M | 104.84%99.51M | 104.84%99.51M | 317.36%99.27M | 317.98%98.77M | 108.05%48.85M |
-Long term capital lease obligation | 31.51%6.92M | 31.51%6.92M | ---- | ---- | -6.88%5.08M | -2.93%5.27M | -2.93%5.27M | 0.09%5.44M | 447.11%5.48M | 396.72%5.45M |
Other non current liabilities | ---- | ---- | --6.67M | --6M | ---- | ---- | ---- | ---- | ---- | ---- |
Total non current liabilities | 2.34%107.22M | 2.34%107.22M | 1.77%106.57M | 1.20%105.5M | 93.29%104.95M | 94.01%104.77M | 94.01%104.77M | 258.32%104.71M | 323.23%104.25M | 120.95%54.3M |
Total liabilities | 11.85%152.47M | 11.85%152.47M | 4.12%142.61M | 2.31%133.38M | 71.89%128.35M | 76.64%136.32M | 76.64%136.32M | 187.35%136.97M | 214.17%130.36M | 71.73%74.67M |
Shareholders'equity | ||||||||||
Share capital | 48.16%363K | 48.16%363K | 48.16%363K | 48.16%363K | 42.63%271K | 29.63%245K | 29.63%245K | 29.63%245K | 63.33%245K | 26.67%190K |
-common stock | 48.16%363K | 48.16%363K | 48.16%363K | 48.16%363K | 30.53%248K | 29.63%245K | 29.63%245K | 29.63%245K | 63.33%245K | 26.67%190K |
-Preferred stock | --0 | --0 | --0 | --0 | --23K | --0 | --0 | --0 | --0 | --0 |
Retained earnings | -11.34%-1.97B | -11.34%-1.97B | -12.60%-1.93B | -12.13%-1.87B | -11.94%-1.82B | -11.14%-1.77B | -11.14%-1.77B | -10.12%-1.72B | -8.51%-1.67B | -7.31%-1.62B |
Paid-in capital | 13.68%2.12B | 13.68%2.12B | 13.80%2.12B | 13.87%2.11B | 23.12%2.11B | 8.98%1.86B | 8.98%1.86B | 9.01%1.86B | 15.35%1.86B | 6.64%1.71B |
Less: Treasury stock | 59.97%4.62M | 59.97%4.62M | 59.97%4.62M | 59.97%4.62M | 59.97%4.62M | 39.98%2.89M | 39.98%2.89M | 39.98%2.89M | 39.98%2.89M | 39.98%2.89M |
Gains losses not affecting retained earnings | 283.87%119K | 283.87%119K | 408.85%349K | -93.00%-193K | 69.33%-50K | 107.24%31K | 107.24%31K | 76.99%-113K | 33.33%-100K | -340.54%-163K |
Total stockholders'equity | 56.75%145.95M | 56.75%145.95M | 27.96%178.51M | 28.77%239.98M | 228.09%288.87M | -20.50%93.11M | -20.50%93.11M | -3.13%139.51M | 163.11%186.36M | -5.02%88.05M |
Total equity | 56.75%145.95M | 56.75%145.95M | 27.96%178.51M | 28.77%239.98M | 228.09%288.87M | -20.50%93.11M | -20.50%93.11M | -3.13%139.51M | 163.11%186.36M | -5.02%88.05M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |